Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Delord

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Journal for Immunotherapy of Cancer|June 15, 2023
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy studySophie Papa, Antonella Adami, Michael Metoudi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22<sup>+</sup> Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic LeukemiaPatrice Chevallier, Thibaut Leguay, Marc Delord, et al.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Journal for Immunotherapy of Cancer|June 15, 2023
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy studySophie Papa, Antonella Adami, Michael Metoudi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22<sup>+</sup> Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic LeukemiaPatrice Chevallier, Thibaut Leguay, Marc Delord, et al.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 7